"Uroplakin III" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A uroplakin subtype that heterodimerizes with UROPLAKIN IB to form a component of the asymmetric unit membrane found in urothelial cells.
| Descriptor ID |
D060171
|
| MeSH Number(s) |
D12.776.395.550.942.300 D12.776.543.550.942.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Uroplakin III".
Below are MeSH descriptors whose meaning is more specific than "Uroplakin III".
This graph shows the total number of publications written about "Uroplakin III" by people in this website by year, and whether "Uroplakin III" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Uroplakin III" by people in Profiles.
-
Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
-
Chronic pelvic allodynia is mediated by CCL2 through mast cells in an experimental autoimmune cystitis model. Am J Physiol Renal Physiol. 2015 Jan 15; 308(2):F103-13.
-
Uroplakin peptide-specific autoimmunity initiates interstitial cystitis/painful bladder syndrome in mice. PLoS One. 2013; 8(8):e72067.
-
Immunohistochemical profile to distinguish urothelial from squamous differentiation in carcinomas of urothelial tract. Hum Pathol. 2013 Feb; 44(2):164-72.
-
UPK3A: a promising novel urinary marker for the detection of bladder cancer. Urology. 2010 Aug; 76(2):514.e6-11.
-
Loss of uroplakin III expression is associated with a poor prognosis in patients with urothelial carcinoma of the upper urinary tract. BJU Int. 2006 Jun; 97(6):1322-6.
-
Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res. 2003 Nov 15; 9(15):5501-7.